

Deborah DeRyckere

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5964505/publications.pdf>

Version: 2024-02-01

45
papers

1,956
citations

304743

22
h-index

345221

36
g-index

48
all docs

48
docs citations

48
times ranked

2787
citing authors

#	ARTICLE	IF	CITATIONS
1	The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 769-785.	28.4	541
2	MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. <i>Journal of Clinical Investigation</i> , 2013, 123, 3231-3242.	8.2	153
3	UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7031-7041.	6.4	125
4	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 2257-2267.	8.2	124
5	Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 129-134.	2.8	67
6	Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2013, 122, 1599-1609.	1.4	62
7	The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. <i>Cancers</i> , 2018, 10, 474.	3.7	60
8	UNC1062, a new and potent Mer inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2013, 65, 83-93.	5.5	58
9	Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations. <i>Clinical Cancer Research</i> , 2015, 21, 1360-1372.	7.0	58
10	UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. <i>Clinical Cancer Research</i> , 2017, 23, 1481-1492.	7.0	58
11	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. <i>JCI Insight</i> , 2016, 1, e85630.	5.0	55
12	UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2367-2377.	4.1	53
13	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. <i>JCI Insight</i> , 2018, 3, .	5.0	51
14	Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2014-2022.	4.1	45
15	MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. <i>Journal of Cellular Biochemistry</i> , 2020, 213, 107577.		43
16	Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 6722-6736.	1.8	38
17	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2297-2308.	4.1	36
18	Characterization of Transcriptional Regulation During Negative Selection <i>In Vivo</i> . <i>Journal of Immunology</i> , 2003, 171, 802-811.	0.8	33

#	ARTICLE	IF	CITATIONS
19	Targeting the TAM Receptors in Leukemia. <i>Cancers</i> , 2016, 8, 101.	3.7	32
20	Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. <i>Oncotarget</i> , 2014, 5, 10434-10445.	1.8	30
21	Discovery of Macrocylic Pyrimidines as MerTK-Specific Inhibitors. <i>ChemMedChem</i> , 2017, 12, 207-213.	3.2	25
22	MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members. <i>Clinical Cancer Research</i> , 2018, 24, 6523-6535.	7.0	25
23	Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. <i>Journal of Hematology and Oncology</i> , 2013, 6, 10.	17.0	24
24	Risk-associated alterations in marrow T cells in pediatric leukemia. <i>JCI Insight</i> , 2020, 5, .	5.0	23
25	Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10242-10254.	6.4	20
26	Design and Synthesis of Novel Macrocylic Mer Tyrosine Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1044-1049.	2.8	19
27	E2F1 and E2F2 Are Differentially Required for Homeostasis-Driven and Antigen-Induced T Cell Proliferation In Vivo. <i>Journal of Immunology</i> , 2005, 175, 647-655.	0.8	15
28	Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5639.	3.7	13
29	Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. <i>Journal of the American Chemical Society</i> , 2019, 141, 15700-15709.	13.7	12
30	Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2022, 13, 1157.	12.8	12
31	MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	12
32	Identification and characterization of transcription factor target genes using gene-targeted mice. <i>Methods</i> , 2002, 26, 57-75.	3.8	10
33	Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML. <i>Blood</i> , 2020, 136, 24-25.	1.4	5
34	Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia. <i>Journal of Visualized Experiments</i> , 2013, , e50720.	0.3	4
35	UNC5293, a potent, orally available and highly MERTK-selective inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113534.	5.5	4
36	The Current State of FLT3 Inhibition in Acute Myeloid Leukemia – Pitfalls and Promises. <i>Journal of Cell Signaling</i> , 2017, 02, .	0.3	3

#	ARTICLE	IF	CITATIONS
37	Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1184-1184.	1.4	3
38	Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies. , 2019, , 61-85.		1
39	Abstract 1109: A novel strategy to cope with osimertinib resistance in non-small cell lung cancer by treatment with a PIM kinase inhibitor in combination with a MERTK-selective kinase inhibitor. , 2021, , .		1
40	Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib. , 2020, , .		1
41	Analysis of Single Cell Transcriptomics in Paired Pediatric T-ALL Samples Collected at Diagnosis and Following End of Induction Therapy Reveals an MRD-Associated Stem Cell Signature. <i>Blood</i> , 2021, 138, 1311-1311.	1.4	1
42	Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling. <i>Blood</i> , 2020, 136, 11-12.	1.4	1
43	Abstract A110: Inhibition of MerTK in tumor infiltrating leukocytes decreases tumor growth in a mouse model of breast cancer. , 2013, , .		0
44	<i>Single Cell RNA Sequencing Driven Characterization of Rare B/Myeloid and T/Myeloid Mixed Phenotype Acute Leukemia</i>. <i>Blood</i> , 2021, 138, 3455-3455.	1.4	0
45	Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia. , 2022, 10, e004774.		0